July 02, 2025 FDA Approves Ready-to-Infuse Vancomycin Tyzavan is the first FDA-approved vancomycin formulation available at room temperature that requires no compounding, thawing, or dilution, enabling faster treatment in time-critical infections like sepsis. Conexiant
June 30, 2025 Structured Exercise Program Improves Survival Outcomes in Patients With Stage III or High-Risk Stage II Colon Cancer The ASCO Post
June 30, 2025 Structured Exercise Program Improves Survival Outcomes in Patients With Stage III or High-Risk Stage II Colon Cancer The ASCO Post
June 25, 2025 Molecular Assay Identifies Patients With Early NSCLC Likely to Benefit From Adjuvant Chemotherapy The ASCO Post
June 17, 2025 Early-Phase Trial Shows Activity and Safety of Zongertinib in Previously Treated HER2-Mutant NSCLC The ASCO Post
June 16, 2025 AACR 2025: Zoldonrasib May Elicit Objective Responses in Patients With KRAS G12D–Mutated NSCLC The ASCO Post
June 16, 2025 AACR 2025: Oral HER2-Targeted Therapy for Advanced HER2-Mutated Lung Cancer The ASCO Post
June 17, 2025 Proposed Budget Cuts to Medicaid May Result in More Than 16,500 Medically Preventable Deaths Annually The ASCO Post